Keyword: Aubagio

A small group of physicians expressed little interest in new MS drugs from Novartis, Merck KGaA and Biogen but favored a repurposed therapy.

New data shows a significant reduction in relapse rates in patients taking Novartis' repurposed cancer drug ofatumumab.

Novartis has new data showing once-monthly injections of Arzerra were better at reducing MS relapses than Sanofi's once-daily pill Aubagio.

Celgene's MS candidate ozanimod might have challenged some big blockbusters in the field, but an FDA decision means it won't happen anytime soon.

Sanofi's Q3 results are feeding fears that its innovation engine may not be able to outpace the decline in its aging diabetes unit.

Merck KGaA has won European approval for its oral MS drug, but competing with more established rivals won't be easy.

A U.S. appeals court sided with Biogen in a lawsuit claiming execs weren't open with investors about Tecfidera's sales trajectory after the death of a patient taking the drug.

Some closely watched new drugs grabbed the spotlight at the American Academy of Neurology meeting this week, and plenty of other therapies put up results worth noting.

Celgene’s late-stage pill, ozanimod, could hit $2b in sales and add pressure to an already competitive oral MS market, analysts say.